Kristof Vercruysse on ”First in Human” Presented at ASH25
Kristof Vercruysse, CEO and Co-Founder at TargED Biopharmaceuticals, reposted from TargED Biopharmaceuticals on LinkedIn:
”Back in town from ASH25.
What a journey and emotional rollercoaster it has been the last days.
Thanks to the full TargED team to make the First in Human happen with positive results and looking forward for more to come.”
Quoting TargED Biopharmaceuticals‘s post:
”We are excited to announce positive results from a Phase 1 study for TargED’s lead investigational thrombolytic fusion protein, TGD001, in an oral presentation at ASH25 in Orlando, Florida today.
The first-in-human clinical trial demonstrated that TGD001 is safe and was well tolerated with no spontaneous bleeding events across four ascending dose cohorts.
TargED Biopharmaceuticals plans to initiate two Phase 1/2 clinical proof-of-concept studies evaluating TGD001 as a potential treatment for patients with acute ischemic stroke (AIS) and thrombotic microangiopathies (TMAs), including immune thrombotic thrombocytopenic purpura (iTTP).
Read the full press release with detailed results.
Stay updated with Hemostasis Today.
-
Sep 19, 2026, 10:52Consuela A. Albright: The Critical Role of Black Blood Donors in Sickle Cell Treatment
-
Sep 19, 2026, 10:47Amber Yates: Inside Agios’ Partnership with the Sickle Cell Community
-
Sep 19, 2026, 10:46Anton Farkas: Mechanical Thrombectomy for Acute PE in Early Pregnancy
-
Sep 19, 2026, 10:40Marjolein Smidt: ASH Raises Ferritin Thresholds for Iron Deficiency
-
Sep 19, 2026, 10:34Nawsherwan Mohammad: ASH 2026 Guidelines Redefine How We Detect Iron Deficiency
-
Sep 19, 2026, 10:21Upcoming Podcast on Thalassaemia with The Lancet Haematology
-
Sep 19, 2026, 10:20Steve Helm: Cardiology and Anticoagulation Pharmacist Role Opens Near NYC
-
Sep 19, 2026, 10:12Omid Seidizadeh: A Great Pleasure to Speak on vWD at the 59th NordCoag Congress
-
Sep 19, 2026, 10:08Carsten Hansen: What Happens During a Sickle Cell Crisis?